TrianglePUBLICATIONS · 36190525
A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Clin Cancer Res
- Publication date
- 2022 Dec 1
- First author
- Davis KL
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Davis KL
- type
- Author
- name
- Fox E
- type
- Author
- name
- Isikwei E
- type
- Author
- name
- Reid JM
- type
- Author
- name
- Liu X
- type
- Author
- name
- Minard CG
- type
- Author
- name
- Voss S
- type
- Author
- name
- Berg SL
- type
- Author
- name
- Weigel BJ
- type
- Author
- name
- Mackall CL
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Davis KL
- type
- Author
- name
- Fox E
- type
- Author
- name
- Isikwei E
- type
- Author
- name
- Reid JM
- type
- Author
- name
- Liu X
- type
- Author
- name
- Minard CG
- type
- Author
- name
- Voss S
- type
- Author
- name
- Berg SL
- type
- Author
- name
- Weigel BJ
- type
- Author
- name
- Mackall CL
- type
- Author
- bibliography ids
- nci-bib-a787708054faea79814f38ff
- book metadata
- content sha256
- 78503c3e57a5d72948cfb51a36bfb0e3e91429aebea6a7ea479cff75cb4786a6
- document type
- citation
- dois
- 10.1158/1078-0432.CCR-22-2164
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:36190525
- immutable id
- pubmed:36190525@78503c3e57a5d72948cfb51a36bfb0e3e91429aebea6a7ea479cff75cb4786a6
- journal
- abbreviation
- Clin Cancer Res
- issn electronic
- 1557-3265
- issn print
- 1078-0432
- issue
- 23
- name
- Clinical cancer research : an official journal of the American Association for Cancer Research
- nlm unique id
- 9502500
- pages
- 5088-5097
- volume
- 28
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 36190525
- provenance
- batch id
- d370e99271168e8a8a13
- provider
- NCBI PubMed ESummary
- record sha256
- 57177c057eabc11c1dae6280f6f9c0d020958bbfd0c21dc22d225a14fafe7e1f
- response sha256
- f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
- retrieved at
- 2026-09-09T23:48:13.005737+00:00
- publication date
- display
- 2022 Dec 1
- precision
- day
- year
- 2022
- publication types
- Clinical Trial, Phase II
- Clinical Trial, Phase I
- Journal Article
- Research Support, Non-U.S. Gov't
- Research Support, N.I.H., Extramural
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.
Preserved source evidence · Not medical advice